Eledon Pharmaceuticals Inc Stock Price, News & Analysis

Eledon Pharmaceuticals (NASDAQ: ELDN) has announced the dosing of the first patient in a Phase 1b study of tegoprubart for kidney transplantation. This open-label trial, authorized in Canada and the UK, aims to enroll 12 patients receiving tegoprubart along with standard induction therapy. It will assess safety, pharmacokinetics, and efficacy, including rates of acute rejection. The study addresses the challenges posed by existing immunosuppressive therapies associated with significant side effects. Eledon sees tegoprubart as a potential game-changer in managing kidney transplants.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced the grant of inducement stock options to new employees covering 180,000 shares at an exercise price of $3.06, closing price on June 6, 2022. These options have a 10-year term and will vest over four years, with 25% vesting after one year. Eledon focuses on developing treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative disorders, primarily through its lead compound, tegoprubart, an anti-CD40L antibody targeting key therapeutic pathways.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced that the FDA has granted orphan drug designation to tegoprubart for preventing allograft rejection in pancreatic islet cell transplantation. This designation follows its prior recognition for treating amyotrophic lateral sclerosis (ALS). Tegoprubart aims to enhance islet transplant outcomes by reducing reliance on calcineurin inhibitors (CNIs), which have adverse effects. The FDA's orphan designation offers financial incentives and a potential seven years of market exclusivity upon approval, marking a significant step for Eledon in developing innovative treatments.

Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on innovative treatments for organ transplantation and autoimmune diseases, announced that CEO David-Alexandre C. Gros will present at the Jefferies Healthcare Conference on June 9, 2022, at 3:30 p.m. ET in New York City. Interested parties can register for the webcast in advance. Eledon is developing tegoprubart, an anti-CD40L antibody targeting CD40 Ligand, aimed at improving outcomes for patients in need of transplants and those suffering from neurodegenerative diseases.

Eledon Pharmaceuticals announced positive topline results from a Phase 2a clinical trial of tegoprubart in patients with amyotrophic lateral sclerosis (ALS). The study demonstrated that tegoprubart was well-tolerated with no serious drug-related adverse events. Dose-dependent reductions in pro-inflammatory biomarkers were observed, alongside a trend in slowing disease progression as assessed by ALSFRS slope. The trial enrolled 54 patients across 13 sites in the US and Canada, with promising implications for future clinical studies.

Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q1 2022 results, showcasing a net loss of $9.9 million ($0.69 per share), up from a loss of $8.5 million ($0.57 per share) in Q1 2021. The increase in losses was primarily due to higher R&D expenses, which totaled $6.6 million, compared to $5.7 million last year. Significant developments include the completion of patient enrollment for the Phase 2a tegoprubart study in ALS, with topline data anticipated in June 2022, and the first patient dosed in the IgA Nephropathy trial, expanding the clinical footprint internationally.

Eledon Pharmaceuticals has initiated a multicenter, open-label Phase 2a study for its drug, tegoprubart, aimed at treating patients with IgA Nephropathy (IgAN), a kidney condition affecting over 150,000 Americans. The study will assess the drug's safety and efficacy based on changes in urine protein levels over 24 weeks, with additional assessments through 96 weeks. Eledon's CEO highlighted the potential of tegoprubart to improve current treatment standards for IgAN, a disease with significant unmet medical needs.

Eledon Pharmaceuticals (NASDAQ: ELDN) will release its Q1 2022 financial results on May 12, 2022, following market close. A conference call and webcast are scheduled for 4:30 p.m. ET to discuss these results. Eledon focuses on developing treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative conditions. Their lead candidate, tegoprubart, targets the CD40 Ligand pathway and shows potential across various therapeutic areas. After the live event, the webcast will be archived on Eledon's website.

Eledon Pharmaceuticals, a clinical stage biopharmaceutical company specializing in treatments for transplant and autoimmune conditions, announced its participation in a fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, at 2:00 p.m. ET. Interested individuals can register for the webcast here. A replay will later be available on the company's website.